Partnering is a key part of Adagene’s growth strategy. We seek to partner to utilize Adagene’s unique skill set to develop therapeutics for new target classes that, if successful, will radically change the treatment paradigm within the target indication.
Adagene also plans to partner our lead antibody programs in combination trials. Due to the cross species reactive nature of the Adagene antibodies, we can take advantage of highly predictive models where we exhibit strong additive or synergistic behavior into the clinical setting.
For further information, please contact [email protected].